BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company focused on neuroscience and immuno-oncology, announced Tuesday positive overall survival or OS data from its Phase 2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) in patients with small cell neuroendocrine prostate cancer or SCNC.